Galectin Therapeutics (GALT)

• Market cap: $199M
• 1 day: -4.87%
• 5 days: -17%
• 1 month: -28.19%
• 3 months: -42.66%
• 6 months: -11.21%
• Year to date: -27.65%
• 1 year: 138.21%
• 5 years: 49.49%
• 10 years: 107.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 15